POSFREA- palonosetron injection, solution

posfrea by

Drug Labeling and Warnings

posfrea by is a Prescription medication manufactured, distributed, or labeled by Avyxa Pharma, LLC, Avyxa Holdings, LLC., Gland Pharma Hyderabad. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Chemotherapy-Induced Nausea and Vomiting in Adults

    POSFREA is indicated for:

    • Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
    • Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses

    1.2 Postoperative Nausea and Vomiting in Adults

    POSFREA is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.

    As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, POSFREA is recommended even where the incidence of postoperative nausea and/or vomiting is low.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosage

    Recommended Dosage for Chemotherapy-Induced Nausea and Vomiting

    • Inject 0.25 mg as a single intravenous dose over 30 seconds.
    • Start the dosing approximately 30 minutes before the start of chemotherapy.

    Recommended Dosage for Postoperative Nausea and Vomiting

    • 0.075 mg as a single intravenous dose over 10 seconds immediately before the induction of anesthesia.

    2.2 Instructions for Intravenous Administration

    •   Do not mix with other drugs.
    •   Flush the infusion line with 0.9% Sodium Chloride Injection, USP before and after administration of POSFREA.
    •   Inspect POSFREA visually for particulate matter and discoloration before administration.
  • 3 DOSAGE FORMS AND STRENGTHS

    POSFREA is sterile, clear, and colorless solution in a single-dose vial:

    • Injection: 0.25 mg palonosetron in 5 mL (0.05 mg/mL)
    • Injection: 0.075 mg palonosetron in 1.5 mL (0.05 mg/mL)
  • 4 CONTRAINDICATIONS

    POSFREA is contraindicated in patients known to have hypersensitivity to the drug or any of its components [see Adverse Reactions (6.2)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity

    Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists.

    5.2 Serotonin Syndrome

    The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT3 receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post- anesthesia care unit or an infusion center.

    Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g. agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic d##rugs. If symptoms of serotonin syndrome occur, discontinue POSFREA and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if POSFREA is used concomitantly with other serotonergic drugs [see Drug Interactions (7.1)].

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The safety of POSFREA has been established from adequate and well-controlled studies of another intravenous formulation of palonosetron HCl [see Clinical Studies (14)]. Below is a display of the adverse reactions of palonosetron HCl in these adequate and well- controlled studies.

    Chemotherapy-Induced Nausea and Vomiting

    In clinical trials for the prevention of nausea and vomiting induced by moderately or highly emetogenic chemotherapy, 1374 adult patients received a single 0.25 mg dose of palonosetron HCl. Adverse reactions were similar in frequency and severity with intravenous palonosetron HCl and ondansetron or dolasetron. The following is a listing of all adverse reactions reported by ≥ 2% of patients in these trials (Table 1).

    Table 1: Adverse Reactions from Chemotherapy-Induced Nausea and Vomiting Studies ≥ 2% in any Treatment Group
    Adverse Reaction
    		Palonosetron HCl
    0.25 mg Intravenous (N=633)
    		Ondansetron 32 mg Intravenous
    (N=410)
    		Dolasetron 100 mg Intravenous
    (N=194)
    Headache
    		 60 (9%)
    		 34 (8%)
    		 32 (16%)
    Constipation
    		 29 (5%)
    		 8 (2%)
    		 12 (6%)
    Diarrhea
    		 8 (1%)
    		 7 (2%)
    		 4 (2%)
    Dizziness
    		 8 (1%)
    		 9 (2%)
    		 4 (2%)
    Fatigue
    		 3 (< 1%)
    		 4 (1%)
    		 4 (2%)
    Abdominal Pain
    		 1 (< 1%)
    		 2 (< 1%)
    		 3 (2%)
    Insomnia
    		 1 (< 1%)
    		 3 (1%)
    		 3 (2%)

    In other studies, 2 subjects experienced severe constipation following a single palonosetron HCl dose of approximately 0.75 mg, three times the recommended dose.

    In clinical trials, the following infrequently reported adverse reactions, assessed by investigators as treatment-related or causality unknown, occurred following administration of palonosetron HCl to adult patients receiving concomitant cancer chemotherapy:

    Cardiovascular: 1%: non-sustained tachycardia, bradycardia, hypotension, < 1%: hypertension, myocardial ischemia, extrasystoles, sinus tachycardia, sinus arrhythmia, supraventricular extrasystoles and QT prolongation. In many cases, the relationship to palonosetron was unclear.

    Dermatological: < 1%: allergic dermatitis, rash.

    Hearing and Vision: < 1%: motion sickness, tinnitus, eye irritation and amblyopia.

    Gastrointestinal System: 1%: diarrhea, < 1%: dyspepsia, abdominal pain, dry mouth, hiccups and flatulence.

    General: 1%: weakness, < 1%: fatigue, fever, hot flash, flu-like syndrome.

    Liver: < 1%: transient, asymptomatic increases in AST and/or ALT and bilirubin. These changes occurred predominantly in patients receiving highly emetogenic chemotherapy.

    Metabolic: 1%: hyperkalemia, < 1%: electrolyte fluctuations, hyperglycemia, metabolic acidosis, glycosuria, appetite decrease, anorexia.

    Musculoskeletal: < 1%: arthralgia.

    Nervous System: 1%: dizziness, < 1%: somnolence, insomnia, hypersomnia, paresthesia.

    Psychiatric: 1%: anxiety, < 1%: euphoric mood.

    Urinary System: < 1%: urinary retention.

    Vascular: < 1%: vein discoloration, vein distention.

    Postoperative Nausea and Vomiting

    The adverse reactions cited in Table 2 were reported in ≥ 2% of adults receiving intravenous palonosetron HCl 0.075 mg immediately before induction of anesthesia in three randomized placebo-controlled trials. Rates of adverse reactions between palonosetron HCl and placebo groups were similar. Some events are known to be associated with, or may be exacerbated by concomitant perioperative and intraoperative medications administered in this surgical population See Clinical Pharmacology (12.2)for thorough QT/QTc study results and data demonstrating the lack of palonosetron effect on QT/QTc.

    Table 2: Adverse Reactions from Postoperative Nausea and Vomiting Studies ≥ 2% in any Treatment Group

    Adverse Reaction
    		Palonosetron HCl 0.075 mg Intravenous
    (N=336)
    		Placebo (N=369)
    Electrocardiogram QT prolongation
    		 16 (5%)
    		 11 (3%)
    Bradycardia
    		 13 (4%)
    		 16 (4%)
    Headache
    		 11 (3%)
    		 14 (4%)
    Constipation
    		 8 (2%)
    		 11(3%)

    In these clinical trials, the following infrequently reported adverse reactions, assessed by investigators as treatment-related or causality unknown, occurred following administration of palonosetron HCl to adult patients receiving concomitant perioperative and intraoperative medications including those associated with anesthesia:

    Cardiovascular: 1% electrocardiogram QTc prolongation, sinus bradycardia, tachycardia; <1%: blood pressure decreased, hypotension, hypertension, arrhythmia, ventricular extrasystoles, generalized edema; ECG T wave amplitude decreased, platelet count decreased. The frequency of these adverse effects did not appear to be different from placebo.

    Dermatological: 1%: pruritus.

    Gastrointestinal System: 1%: flatulence, < 1%: dry mouth, upper abdominal pain, salivary hypersecretion, dyspepsia, diarrhea, intestinal hypomotility, anorexia.

    General: < 1%: chills.

    Liver: 1%: increases in AST and/or ALT< 1%: hepatic enzyme increased

    Metabolic: < 1%: hypokalemia, anorexia.

    Nervous System: < 1%: dizziness.

    Respiratory: < 1%: hypoventilation, laryngospasm.

    Urinary System: 1%: urinary retention.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post approval use of another intravenous formulation of palonosetron HCl. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Very rare cases (<1/10,000) of hypersensitivity reactions including anaphylaxis and anaphylactic shock and injection site reactions (burning, induration, discomfort and pain) were reported from postmarketing experience of palonosetron HCl 0.25 mg in the prevention of chemotherapy- induced nausea and vomiting.

  • 7 DRUG INTERACTIONS

    7.1 Serotonergic Drugs

    Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome. If symptoms occur, discontinue POSFREA and initiate supportive treatment [see Warnings and Precautions (5.2)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no available data on palonosetron HCl use in pregnant women to inform a drug- associated risk. In animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron HCl to rats and rabbits during organogenesis at doses up to 1894 and 3789 times the recommended human intravenous dose, respectively [see Data].

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Data

    Animal Data

    In animal reproduction studies, no effects on embryo-fetal development were observed in pregnant rats given oral palonosetron HCl at doses up to 60 mg/kg/day (1894 times the recommended human intravenous dose based on body surface area) or pregnant rabbits given oral doses up to 60 mg/kg/day (3789 times the recommended human intravenous dose based on body surface area) during the period of organogenesis.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of palonosetron in human milk, the effects of palonosetron on the breastfed infant, or the effects of palonosetron on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for POSFREA and any potential adverse effects on the breastfed infant from palonosetron or from the underlying maternal condition.

    8.4 Pediatric Use

    This product has not been approved for use in pediatric patients for prevention of chemotherapy- induced nausea and vomiting.

    The safety and effectiveness of POSFREA for prevention of postoperative nausea and vomiting have not been established in pediatric patients.

    8.5 Geriatric Use

    Of the 1374 adult cancer patients in clinical studies of intravenously administered palonosetron HCl for CINV, 316 (23%) were aged 65 years and over, while 71 (5%) were aged 75 years and over. Of the 1520 adult patients in clinical studies of intravenously administered palonosetron HCl for PONV, 73 (5%) were age 65 years older [see Clinical Studies (14)]. No overall differences in safety or effectiveness were observed between these subjects and the younger subjects, but greater sensitivity in some older individuals cannot be ruled out. Population pharmacokinetics analysis did not reveal any differences in palonosetron pharmacokinetics between cancer patients ≥ 65 years of age and younger patients. No dose adjustment or special monitoring are required for geriatric patients.

    No overall differences in safety were observed between older and younger subjects in these studies, though the possibility of heightened sensitivity in some older individuals cannot be excluded. No differences in efficacy were observed in geriatric patients for the CINV indication and none are expected for geriatric PONV patients. However, palonosetron HCl efficacy in geriatric patients has not been adequately evaluated.

  • 10 OVERDOSAGE

    There is no known antidote to palonosetron HCl. Overdose should be managed with supportive care.

    Dialysis studies have not been performed, however, due to the large volume of distribution, dialysis is unlikely to be an effective treatment for palonosetron HCl overdose. A single intravenous dose of palonosetron HCl at 30 mg/kg (947 and 474 times the human dose for rats and mice, respectively, based on body surface area) was lethal to rats and mice. The major signs of toxicity were convulsions, gasping, pallor, cyanosis and collapse.

  • 11 DESCRIPTION

    POSFREA Injection contains palonosetron as palonosetron HCl, an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron HCl is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]oct  3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1Hbenz[de]isoquinoline hydrochloride. The empirical formula is C19H24N2O.HCl, with a molecular weight of 332.87. Palonosetron HCl exists as a single isomer and has the following structural formula:

    Image

    Palonosetron HCl is a white to off-white crystalline powder. It is freely soluble in water and soluble in propylene glycol and slightly soluble in ethanol and 2-propanol.

    POSFREA Injection is a sterile, clear, colorless, non-pyrogenic, isotonic, buffered solution for intravenous administration. POSFREA Injection is available as 5 mL single- dose vial or 1.5 mL single dose vial.

    Each mL of aqueous solution contains 0.05 mg palonosetron (equivalent to 0.056 mg palonosetron hydrochloride). Each mL also contains 41.5 mg mannitol, 3.0 mg sodium acetate trihydrate, and water for injection (q.s. to 1.0 mL).

    The pH of the solution in the 5 mL and 1.5 mL vials is 4.5 to 5.5. Hydrochloric acid or sodium hydroxide may have been added to adjust pH.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors.

    Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.

    Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factors and is triggered by release of 5-HT in a cascade of neuronal events involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response.

    12.2 Pharmacodynamics

    Cardiac Electrophysiology

    The effect of intravenous palonosetron on blood pressure, heart rate, and ECG parameters including QTc were comparable to intravenous ondansetron and dolasetron in CINV clinical trials. In PONV clinical trials the effect of palonosetron on the QTc interval was no different from placebo. In non-clinical studies palonosetron possesses the ability to block ion channels involved in ventricular de- and re-polarization and to prolong action potential duration.

    The effect of palonosetron on QTc interval was evaluated in a double blind, randomized, parallel, placebo and positive (moxifloxacin) controlled trial in adult men and women. The objective was to evaluate the ECG effects of intravenously administered palonosetron HCl at single doses of 0.25, 0.75 or 2.25 mg in 221 healthy subjects. At a dose 9 times the maximum recommended dose, palonosetron did not prolong the QT interval to any clinically relevant extent.

    12.3 Pharmacokinetics

    After intravenous dosing of palonosetron HCl in healthy subjects and cancer patients, an initial decline in plasma concentrations is followed by a slow elimination from the body. Mean maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC0-∞) are generally dose proportional over the dose range of 0.3 to 90 mcg/kg in healthy subjects and in cancer patients. Following a single intravenous dose of palonosetron HCl at 3 mcg/kg (or 0.21 mg/70 kg) to six cancer patients, the mean (±SD) maximum plasma concentration was estimated to be 5630 ± 5480 ng/L and the mean AUC was 35.8 ± 20.9 hmcg/L.

    Following intravenous administration of palonosetron HCl 0.25 mg once every other day for 3 doses in 11 cancer patients, the mean increase in plasma palonosetron concentration from Day 1 to Day 5 was 42±34%. Following intravenous administration of palonosetron HCl 0.25 mg once daily for 3 days in 12 healthy subjects, the mean (±SD) increase in plasma palonosetron concentration from Day 1 to Day 3 was 110±45%.

    After intravenous dosing of palonosetron HCl in patients undergoing surgery (abdominal surgery or vaginal hysterectomy), the pharmacokinetic characteristics of palonosetron were similar to those observed in cancer patients.

    Distribution

    Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg. Approximately 62% of palonosetron is bound to plasma proteins.

    Elimination

    After a single intravenous dose of 10 mcg/kg [14C]-palonosetron HCl, approximately 80% of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40% of the administered dose. In healthy subjects, the total body clearance of palonosetron was 0.160 ± 0.035 L/h/kg and renal clearance was 0.067± 0.018 L/h/kg. Mean terminal elimination half-life is approximately 40 hours.

    Metabolism

    Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 6-S-hydroxy-palonosetron. These metabolites each have less than 1% of the 5-HT3 receptor antagonist activity of palonosetron. In vitro metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.

    Excretion

    Palonosetron is partially eliminated from the body through renal excretion.

    Specific Populations

    Renal Impairment

    Mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters. Total systemic exposure increased by approximately 28% in severe renal impairment relative to healthy subjects. This increase is not considered clinically meaningful.

    Hepatic Impairment

    Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects.

    Race/Ethnicity

    The pharmacokinetics of palonosetron were characterized in twenty-four healthy Japanese subjects over an intravenous dose range of 3 to 90 mcg/kg. Total body clearance was 25% higher in Japanese subjects compared to Whites, however, this increase is not considered clinically meaningful. The pharmacokinetics of palonosetron in Blacks have not been adequately characterized.

    Drug Interaction Studies

    In vitro studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.

    Dexamethasone

    Coadministration of 0.25 mg palonosetron HCl and 20 mg dexamethasone administered intravenously in healthy subjects revealed no pharmacokinetic drug-interactions between palonosetron and dexamethasone.

    Oral Aprepitant

    In an interaction study in healthy subjects where a single 0.25 mg intravenous dose of palonosetron HCl was administered on day 1 and oral aprepitant for 3 days (125 mg/80 mg/80 mg), the pharmacokinetics of palonosetron were not significantly altered (AUC: no change, Cmax: 15% increase).

    Metoclopramide

    A study in healthy subjects involving a single 0.75 mg intravenous dose of palonosetron HCl and steady state oral metoclopramide (10 mg four times daily) demonstrated no significant pharmacokinetic interaction.

    Corticosteroids, Analgesics, Antiemetics/Antinauseants, Antispasmodics and Anticholinergic Agents

    In controlled clinical trials, palonosetron HCl has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    In a 104-week carcinogenicity study in CD-1 mice, animals were treated with oral doses of palonosetron HCl at 10, 30 and 60 mg/kg/day. Treatment with palonosetron was not tumorigenic. The highest tested dose produced a systemic exposure to palonosetron (plasma AUC) of about 150 to 289 times the human exposure (AUC= 29.8 hmcg/L) at the recommended intravenous dose of 0.25 mg. In a 104-week carcinogenicity study in Sprague-Dawley rats, male and female rats were treated with oral doses of 15, 30 and 60 mg/kg/day and 15, 45 and 90 mg/kg/day, respectively. The highest doses produced a systemic exposure to palonosetron (plasma AUC) of 137 and 308 times the human exposure at the recommended dose. Treatment with palonosetron HCl produced increased incidences of adrenal benign pheochromocytoma and combined benign and malignant pheochromocytoma, increased incidences of pancreatic Islet cell adenoma and combined adenoma and carcinoma and pituitary adenoma in male rats. In female rats, it produced hepatocellular adenoma and carcinoma and increased the incidences of thyroid C-cell adenoma and combined adenoma and carcinoma.

    Palonosetron was not genotoxic in the Ames test, the Chinese hamster ovarian cell (CHO/HGPRT) forward mutation test, the ex vivo hepatocyte unscheduled DNA synthesis (UDS) test or the mouse micronucleus test. It was, however, positive for clastogenic effects in the Chinese hamster ovarian (CHO) cell chromosomal aberration test.

    Palonosetron HCl at oral doses up to 60 mg/kg/day (about 1894 times the recommended human intravenous dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.

  • 14 CLINICAL STUDIES

    The safety and efficacy of POSFREA have been established based on adequate and well-controlled adult studies of another intravenous formulation of palonosetron HCl in chemotherapy induced nausea and vomiting and postoperative nausea and vomiting. Below is a display of the results of these adequate and well-controlled studies of palonosetron HCl in these conditions.

    14.1 Chemotherapy Induced Nausea and Vomiting in Adults

    Efficacy of a single intravenous dose of palonosetron HCl in preventing acute and delayed nausea and vomiting induced by both moderately and highly emetogenic chemotherapy was studied in 4 trials. In these double-blind studies, complete response rates (no emetic episodes and no rescue medication) and other efficacy parameters were assessed through at least 120 hours after administration of chemotherapy. The safety and efficacy of palonosetron HCl in repeated courses of chemotherapy was also assessed.

    Moderately Emetogenic Chemotherapy

    Two double-blind trials (Study 1 and Study 2) involving 1132 patients compared a single intravenous dose of palonosetron HCl with either a single intravenous dose of ondansetron (Study 1) or dolasetron (Study 2) given 30 minutes prior to moderately emetogenic chemotherapy including carboplatin, cisplatin ≤ 50 mg/m2, cyclophosphamide <1500 mg/m2, doxorubicin > 25 mg/m2, epirubicin, irinotecan, and methotrexate >250 mg/m2. Concomitant corticosteroids were not administered prophylactically in Study 1 and were only used by 4 to 6% of patients in Study 2. The majority of patients in these studies were women (77%), White (65%) and naïve to previous chemotherapy (54%). The mean age was 55 years.

    Highly Emetogenic Chemotherapy

    A double-blind, dose-ranging trial evaluated the efficacy of a single intravenous dose of palonosetron HCl from 0.3 to 90 mcg/kg (equivalent to < 0.1 mg to 6 mg fixed dose) in 161 chemotherapy-naïve adult cancer patients receiving highly-emetogenic chemotherapy (either cisplatin ≥ 70 mg/m2 or cyclophosphamide > 1100 mg/m2). Concomitant corticosteroids were not administered prophylactically. Analysis of data from this trial indicates that 0.25 mg is the lowest effective dose in preventing acute nausea and vomiting induced by highly emetogenic chemotherapy.

    A double-blind trial involving 667 patients compared a single intravenous dose of palonosetron HCl with a single intravenous dose of ondansetron (Study 3) given 30 minutes prior to highly emetogenic chemotherapy including cisplatin ≥ 60 mg/m2, cyclophosphamide > 1500 mg/m2, and dacarbazine. Corticosteroids were co-administered prophylactically before chemotherapy in 67% of patients. Of the 667 patients, 51% were women, 60% White, and 59% naïve to previous chemotherapy. The mean age was 52 years.

    Efficacy Results

    The antiemetic activity of palonosetron HCl was evaluated during the acute phase (0-24 hours) [Table 4], delayed phase (24-120 hours) [Table 5], and overall phase (0-120 hours) [Table 6] post-chemotherapy in Studies 1, 2 and 3.

    Table 4: Prevention of Acute Nausea and Vomiting (0-24 hours): Complete Response Rates

    a Intent-to-treat cohort

    b 2-sided Fisher's exact test. Significance level at α=0.025.

    c These studies were designed to show non-inferiority. A lower bound greater than –15% demonstrates non-inferiority between palonosetron HCl and comparator.

    d Ondansetron 32 mg intravenous was used in the clinical trial. Although this dose was used in the trial, this is no longer the currently recommended dose. Refer to the ondansetron prescribing information for the current recommended dose.

    Chemotherapy
    		Study
    		Treatment Group
    		Na
    		% with Complete Response
    		p-value b
    		97.5% Confidence Interval Palonosetron HCl minus
    Comparator c


    Image
    Moderately Emetogenic
    		 1
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 189
    		 81
    		 0.009
    Ondansetron
    32 mg Intravenousd
    		185
    		 69
    2
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 189
    		 63
    		 NS
    Dolasetron
    100 mg Intravenous
    		 191
    		 53
    Highly Emetogenic
    		 3
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 223
    		 59
    		 NS
    Ondansetron
    32 mg Intravenousd
    		221
    		 57

    These trials show that palonosetron HCl was effective in the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. In Study 3, efficacy was greater when prophylactic corticosteroids were administered concomitantly. Clinical superiority over other 5-HT3 receptor antagonists has not been adequately demonstrated in the acute phase.

    Table 5: Prevention of Delayed Nausea and Vomiting (24-120 hours): Complete Response Rates

    a Intent-to-treat cohort

    b 2-sided Fisher's exact test. Significance level at α=0.025.

    c These studies were designed to show non-inferiority. A lower bound greater than–15% demonstrates noninferiority between palonosetron HCl and comparator.

    d Ondansetron 32 mg intravenous was used in the clinical trial. Although this dose was used in the trial, this is no longer the currently recommended dose. Refer to the ondansetron prescribing information for the current recommended dose.
    Chemotherapy
    		Study
    		Treatment Group
    		Na
    		% with Complete Response
    		p-value b

    97.5% Confidence Interval Palonosetron HCl minus Comparatorc
    Moderately Emetogenic
    		 1
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 189
    		 74
    		 <0.001

    Image
    Ondansetron
    32 mg Intravenousd
    		185
    		 55
    2
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 189
    		 54
    		 0.004
    Dolasetron
    100 mg Intravenous
    		 191
    		 39

    These trials show that palonosetron HCl was effective in the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.

    Table 6: Prevention of Overall Nausea and Vomiting (0-120 hours): Complete Response Rates

    a Intent-to-treat cohort

    b 2-sided Fisher's exact test. Significance level at α=0.025.

    c These studies were designed to show non-inferiority. A lower bound greater than –15% demonstrates non-inferiority between palonosetron HCl and comparator.

    d Ondansetron 32 mg intravenous was used in the clinical trial. Although this dose was used in the trial, this is no longer the currently recommended dose. Refer to the ondansetron prescribing information for the current recommended dose.
    Chemotherapy
    		Study
    		Treatment Group
    		Na
    		% with Complete Response
    		p-value b
    		97.5% Confidence Interval Palonosetron HCl minus Comparator c


    Image
    Moderately Emetogenic
    		 1
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 189
    		 69
    		 <0.001
    Ondansetron
    32 mg Intravenousd
    		185
    		 50
    2
    		 Palonosetron HCl
    0.25 mg Intravenous
    		 189
    		 46
    		 0.021
    Dolasetron
    100 mg Intravenous
    		 191
    		 34

    These trials show that palonosetron HCl was effective in the prevention of nausea and vomiting throughout the 120 hours (5 days) following initial and repeat courses of moderately emetogenic cancer chemotherapy.

    14.2 Postoperative Nausea and Vomiting

    In one multicenter, randomized, stratified, double-blind, parallel-group, clinical trial (Study 1), palonosetron HCl was compared with placebo for the prevention of PONV in 546 patients undergoing abdominal and gynecological surgery. All patients received general anesthesia. Study 1 was a pivotal study conducted predominantly in the US in the out-patient setting for patients undergoing elective gynecologic or abdominal laparoscopic surgery and stratified at randomization for the following risk factors: gender, non-smoking status, history of postoperative nausea and vomiting and/or motion sickness.

    In Study 1 patients were randomized to receive palonosetron HCl 0.025 mg, 0.050 mg or 0.075 mg or placebo, each given intravenously immediately prior to induction of anesthesia. The antiemetic activity of palonosetron was evaluated during the 0 to 72 hour time period after surgery.

    Of the 138 patients treated with 0.075 mg palonosetron HCl in Study 1 and evaluated for efficacy, 96% were women; 66% had a history of PONV or motion sickness; 85% were non smokers. As for race, 63% were White, 20% were Black, 15% were Hispanic, and 1% were Asian. The age of patients ranged from 21 to 74 years, with a mean age of 37.9 years. Three patients were greater than 65 years of age.

    Co-primary efficacy measures were Complete Response (CR) defined as no emetic episode and no use of rescue medication in the 0-24 and in the 24-72 hours postoperatively.

    Secondary efficacy endpoints included:

    • Complete Response (CR) 0-48 and 0-72 hours
    • Complete Control (CC) defined as CR and no more than mild nausea
    • Severity of nausea (none, mild, moderate, severe)

    The primary hypothesis in Study 1 was that at least one of the three palonosetron HCl doses were superior to placebo.

    Results for Complete Response in Study 1 for 0.075 mg palonosetron HCl versus placebo are described in the following table.

    Table 7: Prevention of Postoperative Nausea and Vomiting: Complete Response (CR), Study 1, Palonosetron HCl 0.075 mg Vs Placebo

    * To reach statistical significance for each co-primary endpoint, the required significance limit for the lowest p- value was p<0.017.

    Δ Difference (%): palonosetron HCl 0.075 mg minus placebo
    Treatment
    		n/N (%)
    		Palonosetron HCl Vs Placebo
    Δ
    		p-value*
    Co-primary Endpoints
    CR 0-24 hours
    Palonosetron HCl
    		59/138 (42.8%)
    		 16.8%
    		 0.004
    Placebo
    		35/135 (25.9%)
    CR 24-72 hours
    Palonosetron HCl
    		67/138 (48.6%)
    		 7.8%
    		 0.188
    Placebo
    		55/135 (40.7%)

    Palonosetron HCl 0.075 mg reduced the severity of nausea compared to placebo. Analyses of other secondary endpoints indicate that palonosetron HCl 0.075 mg was numerically better than placebo; however, statistical significance was not formally demonstrated.

    A randomized, double-blind, multicenter, placebo-controlled, dose ranging trial was performed to evaluate intravenous palonosetron HCl for the prevention of post-operative nausea and vomiting following abdominal or vaginal hysterectomy. Five intravenous palonosetron HCl doses (0.1, 0.3, 1.0, 3.0 and 30 μg/kg) were evaluated in a total of 381 intent-to-treat patients. The primary efficacy measure was the proportion of patients with CR in the first 24 hours after recovery from surgery. The lowest effective dose was palonosetron HCl 1 mcg/kg (approximately 0.075 mg) which had a CR rate of 44% versus 19% for placebo, p=0.004. Palonosetron HCl 1 mcg/kg also significantly reduced the severity of nausea versus placebo, p=0.009.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    POSFREATM injection is clear and colorless solution and is supplied in single-dose vials as follows:

    NDC Number
    		Strength
    		Package
    83831-105-01
    		 0.25 mg palonosetron in 5 mL (0.05 mg/mL)
    		 1 vial/carton
    83831-104-05
    		 0.075 mg palonosetron in 1.5 mL (0.05 mg/mL)
    		 5 vials/carton

    Storage

    • Store at 20°C to 25°C (68°F to 77°F); [Excursions permitted to 15°C to 30°C (59°F to 86°F)].
    • Protect from freezing.
    • Protect from light.
  • 17 PATIENT COUNSELING INFORMATION

    Advise patients to read the FDA-approved patient labeling (Patient Information).

    Hypersensitivity Reactions

    Advise patients that hypersensitivity reactions, including anaphylaxis, have been reported in patients with or without known hypersensitivity to other 5-HT3 receptor antagonists. Advise patients to seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur with administration of POSFREA [see Warnings and Precautions (5.1)].

    Serotonin Syndrome

    Advise patients of the possibility of serotonin syndrome, especially with concomitant use of POSFREA and another serotonergic agent such as medications to treat depression and migraines. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, autonomic instability, neuromuscular symptoms with or without gastrointestinal symptoms [see Warnings and Precautions (5.2)].

    Manufactured for:    

    Avyxa Pharma, LLC

    New Jersey 07054, USA

    Revised: 07/2024

    Image

  • SPL PATIENT PACKAGE INSERT

    This Patient Information has been approved by the U.S. Food and Drug Administration.
    PATIENT INFORMATION
    POSFREATM (pos-FREE-uh) (palonosetron) injection, for intravenous use
    Read this Patient Information before you receive POSFREA and each time you receive POSFREA. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
    What is POSFREA?
    POSFREA is a prescription medicine called an "antiemetic."
    POSFREA is used in adults to help prevent the nausea and vomiting that happens:
     ●     right away or later with certain anti-cancer medicines (chemotherapy)
     ●     up to 24 hours while recovering from anesthesia after surgery
    This product has not been approved for use in children to help prevent nausea and vomiting after chemotherapy.
    It is not known if POSFREA is safe and effective in children for the prevention of nausea and vomiting while recovering from anesthesia after surgery.
    Who should not receive POSFREA?
    Do not receive POSFREA if you are allergic to palonosetron hydrochloride or any of the ingredients in POSFREA. See the end of this leaflet for a complete list of ingredients in POSFREA.
    What should I tell my doctor before receiving POSFREA?
    Before receiving POSFREA, tell your doctor about all of your medical conditions, including if you:
     ●     have had an allergic reaction to another medicine for nausea or vomiting
     ●     are pregnant or plan to become pregnant. It is not known if POSFREA will harm your unborn baby.
     ●     are breastfeeding or plan to breastfeed. It is not known if POSFREA passes into your breast milk or if it will affect your baby or your breast milk. Talk to your doctor about the best way to feed your baby if you will receive POSFREA.
    Tell your doctor about all of the medicines you take including prescription and over-the-counter medicines, vitamins and herbal supplements.
    POSFREA and certain other medicines can affect each other, causing serious side effects.
    How will I receive POSFREA?
     ●     POSFREA will be given to you in your vein by intravenous (I.V.) injection.
     ●     POSFREA is usually given about 30 minutes before you receive your anti- cancer medicine (chemotherapy) or right before anesthesia for surgery.
    What are the possible side effects of POSFREA? POSFREA may cause serious side effects, including:
    ●     Serious allergic reactions. POSFREA can cause allergic reactions that can sometimes be serious. Tell your doctor or nurse right away if you have any of the following symptoms of a serious allergic reaction with POSFREA:
    ○    hives
    ○    swollen face
    ○    breathing trouble
    ○    chest pain
    ●     Serotonin Syndrome. A possible life-threatening problem called serotonin syndrome can happen with medicines called 5-HT3 receptor antagonists, including POSFREA, especially when used with medicines used to treat depression and migraine headaches called serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and certain other medicines. Tell your doctor or nurse right away if you have any of the following symptoms of serotonin syndrome:
    ○    agitation, seeing things that are not there (hallucinations), confusion, or coma
    ○    fast heartbeat or unusual and frequent changes in your blood pressure
    ○    dizziness, sweating, flushing, or fever
    ○    tremors, stiff muscles, muscle twitching, overactive reflexes, or loss of coordination
    ○    seizures
    ○    nausea, vomiting, or diarrhea
     ●     The most common side effects of POSFREA in adults who receive POSFREA to help prevent nausea and vomiting that happens with certain anti-cancer medicine (chemotherapy) include: headache and constipation.
     ●     The most common side effects of POSFREA in adults who receive POSFREA to help prevent nausea and vomiting that happens while recovering from anesthesia after surgery include: serious or life-threatening heart rhythm changes (QT prolongation), slow heartbeat, headache, and constipation.
    These are not all the possible side effects of POSFREA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    General information about the safe and effective use of POSFREA
    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your doctor or pharmacist for information about POSFREA that is written for health professionals.
    What are the ingredients in POSFREA?
    Active ingredient: palonosetron hydrochloride
    Inactive ingredients: mannitol and sodium acetate trihydrate in water for intravenous administration.
    Hydrochloric acid or sodium hydroxide may have been added to adjust pH.
    Rx Only
    Manufactured for:
    Avyxa Pharma, LLC
    New Jersey 07054, USA
    For more information call 1-888-520-0954.
    Made in India
    Revised: 07/2024
    		Image
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Posfrea (palonosetron) Injection, 0.25mg/5 mL -Container label

    Posfrea (palonosetron) Injection, 0.25mg/5 mL -Container label

    Posfrea (palonosetron) Injection, 0.25mg/5 mL -Carton label

    Posfrea (palonosetron) Injection, 0.25mg/5 mL -Carton label

  • INGREDIENTS AND APPEARANCE
    POSFREA 
    palonosetron injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 83831-105
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PALONOSETRON HYDROCHLORIDE (UNII: 23310D4I19) (PALONOSETRON - UNII:5D06587D6R) PALONOSETRON0.25 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A)  
    SODIUM ACETATE (UNII: 4550K0SC9B)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 83831-105-011 in 1 CARTON09/30/2024
    15 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20305009/30/2024
    POSFREA 
    palonosetron injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 83831-104
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PALONOSETRON HYDROCHLORIDE (UNII: 23310D4I19) (PALONOSETRON - UNII:5D06587D6R) PALONOSETRON0.075 mg  in 1.5 mL
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A)  
    SODIUM ACETATE (UNII: 4550K0SC9B)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 83831-104-055 in 1 CARTON09/30/202409/30/2024
    11.5 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20305009/30/202409/30/2024
    Labeler - Avyxa Pharma, LLC (128918748)
    Registrant - Avyxa Holdings, LLC. (119187191)
    Establishment
    NameAddressID/FEIBusiness Operations
    Gland Pharma Hyderabad918601238ANALYSIS(83831-105, 83831-104) , API MANUFACTURE(83831-105, 83831-104) , LABEL(83831-105, 83831-104) , MANUFACTURE(83831-105, 83831-104) , PACK(83831-105, 83831-104)

    • Trademark Results [posfrea]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    POSFREA
    POSFREA
    98355367 not registered Live/Pending
    Avyxa Pharma LLC
    2024-01-12
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.